ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 133

Impact of the Five Components of the Euroqol 5-Dimensions Instrument on Healthcare and Work-Loss Costs in Rheumatoid Arthritis: Observational Data from Southern Sweden

Anders Gülfe1, Tor Olofsson1, Jonas K Söderling2, Martin Neovius2 and Johan K Wallman1, 1Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden, 2Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: anti-TNF therapy, Economics, patient-reported outcome measures and rheumatoid arthritis (RA), Work Disability

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Epidemiology and Public Health Poster I: Rheumatoid Arthritis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Healthcare and work-loss costs are markedly higher in RA patients than in the general population. The EuroQol 5-Dimensions (EQ-5D) instrument, commonly applied to measure utility and quality-adjusted life-years (QALYs) in health-economic evaluations, is based on a questionnaire, asking respondents to value 5 health dimensions (mobility; self-care; usual activities; pain/discomfort; anxiety/depression) on a 3-leveled scale. In this study, we aimed to compare how these 5 EQ-5D components relate to healthcare, work-loss, and total societal costs in RA.

Methods: Clinical visits of anti-TNF treated RA patients, monitored in the observational South Swedish Arthritis Treatment Group register 2005-2011, were included (11674 visits in 2246 patients; >95% fulfillment of 1987 ACR criteria in a prior validation). EQ-5D questionnaire responses at visits were linked to register-derived costs of anti-rheumatic drugs, out- and inpatient care, and work-loss due to sick leave or disability pension from 30 days before to 30 days after each visit. Associations of the 5 EQ-5D components to healthcare (patient care and drugs), work-loss (in patients <65 years), and total societal costs (healthcare + work-loss costs; <65 years) were studied in separate, adjusted, generalized estimating equations regression models, comparing standardized β coefficients by nonparametric bootstrapping to assess which component best reflects costs.

Results: The strongest associations with both healthcare and work-loss (and thus also societal) costs were observed for the usual activites component (p<0.05 vs. all other components; Figure). Apart from that, the mobility and self-care components were more closely associated with healthcare costs than anxiety/depression, while stronger associations with work-loss costs were revealed for mobility and anxiety/depression than for pain/discomfort. For comparison, cost associations with the composite EQ-5D utility score (United Kingdom peference set) were (standardized β (95%CI)): -0.11 (-0.14 to -0.09) for healthcare, -0.07 (-0.08 to -0.05) for work-loss, and -0.12 (-0.15 to -0.09) for societal costs.

Conclusion: Of the 5 EQ-5D components, problems to perform one’s usual daily activities was most strongly related to both healthcare and work-loss (as expected) costs. Moreover, the associations of the usual activities component to costs were on par with those observed for the composite EQ-5D utility score, making it an interesting simple marker of total societal costs in RA. Somewhat unexpectedly, relatively weak cost associations were observed regarding the pain/discomfort component.


Disclosure: A. Gülfe, None; T. Olofsson, None; J. K. Söderling, AbbVie, Merck, Novartis, Shire, 5; M. Neovius, Schering-Plough, AstraZeneca, Novo Nordisk, Pfizer, Roche, 2,Pfizer, Abbott, 5; J. K. Wallman, AbbVie, Celgene, Novartis, UCB, 5.

To cite this abstract in AMA style:

Gülfe A, Olofsson T, Söderling JK, Neovius M, Wallman JK. Impact of the Five Components of the Euroqol 5-Dimensions Instrument on Healthcare and Work-Loss Costs in Rheumatoid Arthritis: Observational Data from Southern Sweden [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/impact-of-the-five-components-of-the-euroqol-5-dimensions-instrument-on-healthcare-and-work-loss-costs-in-rheumatoid-arthritis-observational-data-from-southern-sweden/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2017

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-the-five-components-of-the-euroqol-5-dimensions-instrument-on-healthcare-and-work-loss-costs-in-rheumatoid-arthritis-observational-data-from-southern-sweden/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology